Ghent, Belgium, 20 June 2019 – Confo Therapeutics, an emerging drug discovery company, today announces that it has been awarded a €1.7 million grant from Flanders Innovation & Entrepreneurship (VLAIO). The grant will run over two years and will support one of the Company’s proprietary pre-clinical programs, targeting a neurological orphan indication.
The grant will also support translational biology work by Confo alongside the teams of Prof Patrik Verstreken (VIB-KU Leuven Center for Brain & Disease Research), Prof Peter de Witte (Molecular Biodiscovery, KU Leuven) and Prof Guy Bormans (Radiopharmaceutical Research, KU Leuven).
Cedric Ververken, CEO of Confo Therapeutics, commented: “This new grant will allow us to progress novel GPCR-modulating compounds against a neurological orphan indication further into pre-clinical development. We are excited about the potential of our approach to treating this particular indication and are grateful to VLAIO for its support of this project.”
Christel Menet, CSO of Confo Therapeutics, added: “This programme is the result of a new proprietary ConfoBodyTM-based screening technology that was developed under a previous VLAIO grant. We would like to thank VLAIO for its continued support of our work, and look forward to working with our academic partners to generate novel therapeutic options in this area of significant unmet medical need.”